
|Articles|August 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 8
- Volume 4
- Issue 8
Cancer -Related Legislation Introduced
HR1579, introduced by Rep. Brown (D-OH), to require providers of home infusion therapy to be licensed and to limit physician referrals for home infusion therapy services in which the physician has a financial interest.
Advertisement
- HR1579, introduced by Rep. Brown (D-OH), to require providersof home infusion therapy to be licensed and to limit physicianreferrals for home infusion therapy services in which the physicianhas a financial interest.
- HR1614, introduced by Rep. Durbin (D-IL), to amend provisionsof Title XVIII of the Social Security Act relating to Medigappolicies to eliminate age rating in premiums.
- HR1668, introduced by Rep. Danner (D-MO), to establish a programto control fraud and abuse in the Medicare program, and to increasethe amount of civil monetary penalties that may be assessed againstindividuals and entities committing fraud against Medicare.
- S827, introduced by Sen. Pressler (R-SD), to amend the InternalRevenue Code of 1986 to limit an employer's deduction for health-carecosts of its employees if the employer fails to honor its commitmentto provide care to retirees.
- S863, introduced by Sen. Grassley (R-IA), to amend Title XVIIIof the Social Security Act to provide for increased Medicare reimbursementfor physician assistants, to increase the delivery of health servicesin areas that have a shortage of health professionals.
- S872, introduced by Sen. Bond (R-MO), to provide for establishmentof a modernized and simplified health information network foruse by Medicare and Medicaid.
Articles in this issue
almost 31 years ago
CA 125 Predicts Response to Chemo in Ovarian Caalmost 31 years ago
Biochemical Modulation Promising in RT-Resistant GI Canceralmost 31 years ago
Cancer Institute of NJ Adds to its Staffalmost 31 years ago
A Century of Breast Cancer Litigation Is 'Deconstructed'almost 31 years ago
New Depot Formulation of LHRH Analogue Allows 12-Week Dosingalmost 31 years ago
NSABP Investigation Threatens Academic Freedom for All: Fisheralmost 31 years ago
Cancer Fax Directory in 3rd Editionalmost 31 years ago
HIV-Related Malignancies Increasing, Physicians Tell Panelalmost 31 years ago
Breast Cancer Risk Factors Remain Elusive TargetAdvertisement
Related Content
Advertisement


TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi



Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
4
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
5

















































